Vidarabine

Vidarabine, also known by its chemical name adenine arabinoside or Ara-A, is an antiviral medication used topically for the treatment of ocular infections caused by feline herpesvirus type 1 (FHV-1) in cats. Originally developed from cultures of Streptomyces antibioticus and approved for human herpesviral infections, vidarabine has found important application in veterinary ophthalmology as an off-label treatment for herpetic eye disease in cats. The medication is particularly valued for its generally excellent tolerability in feline patients, often being better tolerated than some alternative topical antivirals, making it a useful option for cats requiring antiviral therapy for ocular herpes.

Vidarabine works through a mechanism distinct from the thymidine analogs like idoxuridine and trifluridine. As an adenosine analog, vidarabine is phosphorylated by cellular enzymes to its active triphosphate form, vidarabine triphosphate. This active compound interferes with viral DNA synthesis by inhibiting viral DNA polymerase, thereby preventing the virus from replicating within infected cells. This different mechanism of action compared to thymidine analogs means that vidarabine may be effective in cases where other antivirals have not achieved adequate response, as resistance patterns may differ between drug classes.

The medication is available as a 3% ophthalmic ointment formulation. The ointment vehicle offers certain practical advantages, including longer contact time with the ocular surface compared to solution formulations and a lubricating effect that may be soothing for inflamed eyes. Vidarabine is no longer commercially manufactured as a ready-to-use product in many regions but can be obtained through compounding pharmacies that prepare it specifically for veterinary use. The ointment is applied directly to the affected eye, typically five to six times daily during active treatment, following the general principle that applies to all virostatic antivirals.

While vidarabine is too toxic for systemic administration due to its effects on host DNA synthesis, the topical ophthalmic route results in minimal systemic absorption, allowing safe use for ocular herpetic disease. The medication is considered to have moderate antiviral potency against FHV-1 in laboratory studies, falling between trifluridine (more potent) and acyclovir (less potent) in comparative efficacy assessments. However, clinical response depends on multiple factors beyond in vitro potency, and vidarabine remains a valuable option in the veterinary antiviral armamentarium. Veterinary supervision is important for appropriate diagnosis, treatment selection, and monitoring throughout therapy.

The primary indication for vidarabine in cats is the treatment of ocular disease caused by feline herpesvirus type 1 (FHV-1), which is the most common infectious cause of conjunctivitis and keratitis in domestic cats. FHV-1 is ubiquitous in the feline population, with most cats exposed early in life and many becoming latently infected. Recurrent episodes of ocular disease can occur when the latent virus reactivates, typically during periods of stress or immunosuppression. Vidarabine provides a topical antiviral option for managing these active ocular infections.

Herpetic keratitis is a key indication for vidarabine therapy. Cats with FHV-1 keratitis may present with corneal ulceration, including the characteristic dendritic ulcers that are highly suggestive of herpesvirus infection. The corneal disease causes ocular pain, manifesting as blepharospasm, excessive tearing, and avoidance of bright light. Vidarabine applied to the affected eye works to suppress viral replication in the corneal epithelium, allowing the tissue to heal. The medication's good tolerability in cats makes it a practical choice for the frequent daily applications required during treatment.

Herpetic conjunctivitis, with or without concurrent corneal involvement, is another indication for vidarabine use. Cats with FHV-1 conjunctivitis typically exhibit conjunctival redness, swelling, and discharge that may be clear initially and become purulent with secondary bacterial infection. While mild conjunctivitis often resolves without specific antiviral treatment, more persistent or severe cases may benefit from antiviral therapy. Vidarabine's ointment formulation provides extended contact with the conjunctival surface and may offer soothing lubrication for inflamed tissues.

Vidarabine may be particularly useful in cats that have not responded adequately to other topical antivirals or in those that cannot tolerate alternative medications. Because vidarabine affects a different step in viral replication than the thymidine analogs (idoxuridine and trifluridine), it may be effective in cases where those medications have failed, potentially due to different resistance patterns. Similarly, cats that experience significant irritation from trifluridine, which is common in feline patients, may tolerate vidarabine better and be able to complete their treatment course more successfully.

The selection of vidarabine versus alternative antivirals depends on several factors that the veterinarian considers for each individual patient. Availability is a practical consideration, as vidarabine typically requires compounding and may not be immediately accessible in all areas. Cost may also influence selection, as compounded medications can vary in price. Previous treatment history, including response to and tolerability of other antivirals, helps guide selection. For many veterinarians, the choice between available topical antivirals often comes down to balancing efficacy expectations with the practical realities of owner compliance and patient tolerance, areas where vidarabine's good tolerability profile provides an advantage.

Vidarabine dosing for feline herpesvirus ocular infections follows established protocols adapted from human ophthalmic use. The standard formulation is a 3% ophthalmic ointment, with application to the affected eye or eyes as directed by the prescribing veterinarian. As with all virostatic antivirals, consistent and frequent dosing is essential to maintain drug presence at the site of infection and prevent viral recovery between applications. Cat owners should receive detailed instructions on proper administration technique to maximize treatment effectiveness.

The typical dosing frequency for vidarabine in cats is application to the affected eye five to six times daily, approximately every four to five hours during waking hours. This frequent application schedule reflects the virostatic mechanism of the medication and the need to maintain continuous antiviral activity. While this schedule is demanding, many cat owners find the ointment formulation somewhat easier to apply than eye drops, and cats often tolerate the ointment well, facilitating compliance. Establishing a consistent daily routine helps ensure doses are not missed.

Treatment duration with vidarabine varies depending on the severity of infection and clinical response but typically ranges from seven to fourteen days for acute infections, with some cases requiring longer treatment. The veterinarian should be consulted to determine appropriate treatment duration for each individual case. Unlike some antivirals with strict limitations on treatment duration due to toxicity concerns, vidarabine's good tolerability profile provides some flexibility in treatment length when longer courses are clinically indicated, though prolonged use of any topical medication warrants monitoring.

Proper administration technique helps ensure effective drug delivery while maintaining good tolerability. Hands should be washed before and after administration. To apply the ointment, the cat should be gently restrained, and the lower eyelid pulled down slightly to create a small pocket. A thin ribbon of ointment, approximately one-quarter to one-half inch in length, is applied into this pocket. The tube tip should not touch the eye or eyelid to prevent contamination. After application, the eye can be gently closed briefly to help distribute the ointment across the ocular surface. The ointment will cause temporary blurring of vision, which is normal and resolves as the medication distributes.

If a dose of vidarabine is missed, it should be applied as soon as remembered, and the regular schedule resumed. There is no need to apply extra ointment to compensate for missed doses. Given the frequent dosing required, occasional missed doses are understandable and usually do not significantly impact treatment outcome if most doses are administered as scheduled. However, consistently poor compliance will reduce treatment effectiveness, and caregivers having difficulty maintaining the schedule should discuss alternatives with their veterinarian.

Completion of the prescribed treatment course is important to ensure adequate suppression of the viral infection and allow tissue healing. Even if symptoms appear to resolve before the prescribed end date, continuing treatment as directed helps prevent recurrence due to residual viral activity. The veterinarian should provide guidance on when it is appropriate to discontinue treatment and what follow-up, if any, is needed to confirm resolution.

Vidarabine is generally well-tolerated when used topically in cats, with a favorable side effect profile compared to some alternative antiviral medications. This good tolerability is one of the medication's primary advantages and contributes to its usefulness in feline patients that may not tolerate other options. Understanding the potential side effects, though typically mild, helps cat owners monitor their pets appropriately during treatment and know when to seek veterinary guidance.

Mild local irritation at the site of application is the most commonly observed side effect of vidarabine ophthalmic ointment. Some cats may exhibit mild stinging or discomfort upon application, though this is generally less pronounced than the irritation commonly seen with trifluridine. Signs of mild irritation may include transient blepharospasm (squinting) or increased blinking immediately after application. This discomfort is usually brief and does not prevent continued treatment in most cats.

Increased tearing or mild conjunctival redness may occur during vidarabine treatment. These effects can be difficult to distinguish from the symptoms of the underlying herpesvirus infection being treated. If these signs appear to worsen significantly during treatment or if new symptoms develop, the veterinarian should be consulted to assess whether the changes represent treatment effects, progression of the underlying disease, or another issue requiring attention.

The ointment vehicle causes temporary blurring of vision after application, which is an expected effect of any ophthalmic ointment rather than a true side effect. This blurring occurs because the oily ointment base temporarily coats the cornea before distributing across the ocular surface and being cleared by natural tear film activity. The vision changes are temporary and do not harm the eye. Cats may appear to have slightly impaired vision or be more cautious in their movements immediately after treatment, which resolves within minutes.

Prolonged use of any topical antiviral, including vidarabine, carries theoretical risk of corneal toxicity due to effects on rapidly dividing corneal epithelial cells. While vidarabine is generally considered to have less corneal toxicity potential than some alternatives, extended treatment courses should involve appropriate monitoring. Signs that might suggest corneal toxicity include delayed healing of ulcers, new corneal changes, or worsening despite treatment. Regular veterinary assessment during treatment helps detect any such concerns early.

Serious adverse effects from topical vidarabine use are uncommon. Systemic toxicity is not expected with ophthalmic administration due to minimal systemic absorption. Allergic reactions are rare but possible with any medication. Signs of allergic reaction might include severe periocular swelling, marked conjunctival changes, or skin reactions around the eye. Any suspected allergic reaction should prompt discontinuation and veterinary evaluation. Overall, vidarabine's side effect profile supports its reputation as one of the better-tolerated topical antivirals for feline patients.

While vidarabine is considered one of the safer topical antiviral options for cats, several contraindications and precautions apply to its use. Understanding these limitations helps ensure appropriate patient selection and safe medication use. Veterinarians evaluate each cat individually to determine whether vidarabine therapy is indicated and suitable given the patient's specific circumstances.

Cats with known hypersensitivity to vidarabine or any component of the ophthalmic ointment formulation should not receive the medication. Although allergic reactions to vidarabine are uncommon, any cat that has previously experienced signs of allergic response to this medication should not be retreated. Signs of allergic reaction might include severe periocular swelling, marked conjunctival changes beyond those attributable to the underlying infection, or skin reactions around the application site.

Systemic administration of vidarabine is contraindicated in cats. While this medication is used safely as a topical ophthalmic treatment, vidarabine is too toxic for systemic use due to its inhibitory effects on host DNA synthesis as well as viral DNA. Systemic administration could cause bone marrow suppression and other toxicities. The medication should only be applied topically to the eye as directed and should never be given orally, by injection, or by any other systemic route. Cat owners should be clearly instructed that the medication is for eye use only.

Vidarabine use during pregnancy requires careful consideration. Although topical ophthalmic administration results in minimal systemic absorption, vidarabine has been shown to be mutagenic and teratogenic in some studies. The safety of vidarabine during feline pregnancy has not been established, and the potential risks to developing fetuses must be weighed against the benefits of treating the queen's ocular disease. For pregnant cats with herpetic ocular disease, the veterinarian should discuss the potential risks and consider whether alternative treatments or delayed therapy might be appropriate. Similarly, the safety of vidarabine in lactating queens has not been definitively established, though the minimal systemic absorption from topical ophthalmic use suggests low risk.

Cats requiring treatment for ocular conditions other than herpesvirus infections should not receive vidarabine, as the medication has no activity against bacteria, fungi, or other pathogens. Accurate diagnosis of FHV-1 involvement is important before initiating antiviral therapy. Using vidarabine for non-viral ocular conditions would delay appropriate treatment while potentially contributing to local irritation without benefit. Veterinary evaluation to confirm or strongly suspect FHV-1 as the cause of ocular disease should precede antiviral treatment.

Drug interactions with topically applied vidarabine are generally limited due to the minimal systemic absorption achieved with ophthalmic use. However, several considerations apply when vidarabine is used alongside other medications, particularly other topical ophthalmic treatments. Cat owners should inform their veterinarian of all medications and supplements their cat receives to allow for appropriate interaction assessment and management.

When multiple topical ophthalmic medications are prescribed concurrently, appropriate spacing between applications is important to optimize absorption and effectiveness of each medication. A general guideline is to wait at least five to ten minutes between different eye medications to prevent dilution or washout effects. When using both solution and ointment formulations, solutions are typically administered first because ointment creates a lipid barrier that could impede absorption of subsequently applied aqueous medications. The veterinarian should provide specific guidance on the sequence and timing of multiple eye medications.

The concurrent use of topical corticosteroids with vidarabine requires careful consideration based on the specific clinical situation. Corticosteroids are generally contraindicated during active epithelial herpetic disease because they can enhance viral replication and worsen the infection. However, certain FHV-1 associated conditions such as stromal keratitis or eosinophilic keratitis may benefit from anti-inflammatory therapy once active epithelial disease is controlled. The decision to use topical steroids concurrently with antiviral therapy should be made by the veterinarian, ideally one with ophthalmologic expertise, based on careful assessment of the individual case.

Combination therapy with other topical antivirals is generally not employed, as adding a second topical antiviral is unlikely to provide significant additional benefit while potentially increasing local irritation or toxicity. If a cat has not responded adequately to one topical antiviral, switching to an alternative agent is typically preferred over combination therapy. However, systemic antivirals such as oral famciclovir may be combined with topical vidarabine in severe cases requiring comprehensive antiviral coverage, as the different routes of administration provide complementary coverage without duplicate local effects.

Topical antibiotics are frequently used concurrently with vidarabine when secondary bacterial infection is present or suspected. Herpesviral ocular disease can disrupt the corneal epithelium and compromise ocular surface defenses, predisposing to bacterial infection. The combination of antiviral and antibiotic therapy addresses both the viral cause and bacterial complication. Appropriate spacing between medications applies as noted above. Selection of antibiotic should be based on suspected or confirmed bacterial involvement.

L-lysine supplementation, sometimes recommended for cats with FHV-1 infections, does not interact with vidarabine and may be continued during topical antiviral therapy if desired. However, recent evidence has raised questions about the efficacy of lysine supplementation for FHV-1, and veterinarians may or may not recommend its continued use. Other systemic medications the cat receives are unlikely to interact significantly with topically applied vidarabine given the minimal systemic absorption achieved with ophthalmic administration.

Several important precautions and warnings apply to the use of vidarabine in cats. Awareness of these considerations helps ensure safe and effective therapy while minimizing risks. Both veterinary professionals and cat owners should understand these precautions to optimize treatment outcomes for feline patients with herpetic ocular disease.

Accurate diagnosis of feline herpesvirus type 1 as the cause of ocular disease should ideally precede initiation of vidarabine therapy. While the clinical presentation of herpes keratitis may be characteristic, particularly when dendritic ulcers are present, other causes of corneal and conjunctival disease exist that would not respond to antiviral treatment. Misdiagnosis could result in inappropriate treatment, progression of the actual underlying condition, and unnecessary medication exposure. Diagnostic testing for FHV-1 via PCR of ocular swabs may be helpful in confirming the diagnosis, particularly in cases with atypical presentations.

Regular monitoring during treatment helps ensure appropriate response and early detection of any problems. Cat owners should watch for signs suggesting either inadequate treatment response (worsening or unchanging symptoms) or potential adverse effects (excessive irritation, new symptoms). Veterinary rechecks during treatment may be recommended, particularly for severe infections or cats showing concerning signs. Complete ophthalmologic examination including fluorescein staining can help assess treatment progress and identify any complications.

Proper handling and administration technique helps maintain medication sterility and treatment effectiveness. The ointment tube tip should never contact the eye, eyelid, or any other surface to prevent bacterial contamination that could introduce infection to the already compromised ocular surface. Hands should be washed before and after administering the medication. The tube should be stored according to label directions when not in use, typically at room temperature away from excessive heat or light.

Vidarabine is available only through compounding pharmacies in most regions, as commercial ophthalmic preparations are no longer widely manufactured. When obtaining compounded medications, using a reputable compounding pharmacy that adheres to quality standards is important to ensure product quality and appropriate drug concentration. The veterinarian can often recommend compounding pharmacies experienced in preparing veterinary ophthalmic medications. Compounded products should be used within the timeframe specified by the pharmacy.

Cat owners should understand that topical antiviral therapy treats active viral disease but does not eliminate latent virus or prevent future recurrences. Most cats that develop clinical FHV-1 ocular disease become latently infected and may experience recurrent episodes throughout their lives, typically triggered by stress. Long-term management strategies including stress minimization, environmental optimization, and prompt recognition of early recurrence signs complement acute antiviral treatment. The veterinarian can provide guidance on comprehensive management of this chronic condition.

Proper storage and handling of vidarabine ophthalmic ointment helps maintain medication stability, sterility, and effectiveness throughout the treatment course. As vidarabine is typically obtained through compounding pharmacies rather than as a commercial product, following the specific storage instructions provided by the pharmacy is particularly important. General guidelines for ophthalmic ointment storage and handling apply.

Vidarabine ophthalmic ointment is typically stored at room temperature, generally between 15°C and 30°C (59°F to 86°F), unless otherwise specified on the product label. The medication should be protected from excessive heat, which could affect the ointment consistency and potentially drug stability. Storage near heat sources such as radiators, sunny windows, or hot appliances should be avoided. The ointment should not be refrigerated unless specifically directed by the compounding pharmacy, as inappropriate storage temperatures could affect the formulation.

Protection from light helps maintain medication stability, as vidarabine may be sensitive to light degradation. The ointment tube should be stored in its original packaging or in a dark location when not in use. Storing the medication in a medicine cabinet or drawer that remains closed except during use provides adequate light protection. The tube cap should be replaced securely after each use to protect the medication and maintain sterility.

Maintaining sterility of the ophthalmic ointment is essential to prevent introduction of bacteria to the already compromised ocular surface. The tube tip should never contact the eye, eyelid, skin, or any other surface during application. If accidental contamination of the tip occurs, the veterinarian should be consulted about whether to continue using the product or obtain a replacement. Hands should be washed before handling the medication tube to prevent transfer of bacteria. The tube should not be shared between different animals.

Compounded medications typically have specified beyond-use dates that may be shorter than commercial product expiration dates. The beyond-use date provided by the compounding pharmacy should be noted and the medication discarded after this date, even if some product remains. Using medications beyond their appropriate date risks reduced potency and potential contamination. If treatment extends beyond the original beyond-use date, a new supply should be obtained.

Disposal of unused or expired vidarabine should follow appropriate guidelines. The medication should not be discarded in regular household trash where it might be accessed by children or animals, and should not be disposed of in drains or wastewater. Many pharmacies and veterinary offices accept unused medications for proper disposal. Local pharmaceutical take-back programs may also accept veterinary medications. The veterinarian or pharmacist can advise on appropriate disposal methods in compliance with local regulations.

Feline herpesvirus type 1 affects cats of all breeds, and vidarabine can be used for treating herpetic ocular disease regardless of breed. No specific breed-related contraindications to vidarabine have been identified, though certain breed characteristics may influence the presentation of FHV-1 disease or treatment considerations. Understanding these factors helps optimize care while recognizing that the fundamental approach to treating herpetic eye disease is similar across all feline breeds.

Some purebred cat populations may have higher prevalence of FHV-1 related disease, potentially reflecting increased exposure in cattery environments and possible genetic factors affecting immune responses or ocular anatomy. Breeds mentioned in literature as potentially having increased FHV-1 issues include Persians, Himalayans, and other brachycephalic breeds, though this reflects disease susceptibility rather than any difference in response to vidarabine treatment. Cats of any breed with FHV-1 ocular disease can be treated with vidarabine using standard protocols.

Brachycephalic breeds with prominent eyes and distinctive facial conformation present certain practical considerations for ophthalmic treatment. The prominent eye position in breeds like Persians and Himalayans may make medication application somewhat easier in terms of access to the eye. However, these breeds often have concurrent tear film abnormalities, including reduced tear production or poor tear film quality, that can complicate ocular surface disease. The ointment formulation of vidarabine may provide some lubricating benefit in addition to antiviral activity for these patients. Pre-existing ocular conditions common in brachycephalic breeds should be considered in the overall treatment plan.

Breeds predisposed to corneal sequestrum formation deserve special mention. Persians, Himalayans, and related breeds have increased incidence of this condition, which involves focal corneal necrosis that may be associated with chronic herpesvirus infection among other causes. While vidarabine addresses active viral infection, corneal sequestra may require surgical intervention and additional management beyond antiviral therapy. Cats of predisposed breeds with herpetic disease should be monitored for sequestrum development.

Size variations between breeds do not significantly affect vidarabine dosing, as the standard approach of applying a thin ribbon of ointment to the eye applies regardless of cat size. The small eye size of cats relative to humans means that the standard application provides adequate drug delivery. Very small cats or kittens may require somewhat less ointment per application, but the general approach remains consistent.

Temperament variations across breeds and individuals may influence practical aspects of treatment administration. Some cats tolerate ophthalmic medication application calmly while others are more resistant. The good tolerability of vidarabine compared to some alternatives may be particularly advantageous for cats that are sensitive to eye medications. For cats that remain difficult to treat despite vidarabine's gentle nature, the veterinarian may discuss alternative treatment approaches or strategies for improving compliance.

Several medications related to vidarabine are used in the treatment of feline herpesvirus type 1 ocular disease. Understanding the relationships between these agents helps contextualize treatment options and provides information about alternatives when vidarabine is not suitable, unavailable, or insufficient as monotherapy. The choice among available antivirals depends on factors including efficacy, tolerability, availability, cost, and the specific clinical circumstances.

Idoxuridine is a nucleoside analog topical antiviral that is often considered alongside vidarabine for feline herpetic keratitis. Like vidarabine, idoxuridine is generally well tolerated by cats and is available as a compounded ophthalmic preparation. Idoxuridine is a thymidine analog that works through a different mechanism than vidarabine, which is an adenosine analog. This mechanistic difference may be clinically relevant if one drug fails and alternative therapy is needed, as cross-resistance is less likely between drugs with different mechanisms. In vitro studies suggest idoxuridine has higher antiviral potency against FHV-1 than vidarabine, though clinical response depends on many factors beyond laboratory potency.

Trifluridine is another thymidine analog topical antiviral with demonstrated activity against FHV-1. In vitro studies indicate trifluridine is the most potent of the commonly used topical antivirals against FHV-1. However, trifluridine is frequently poorly tolerated by cats, causing significant ocular irritation that can impair compliance and make treatment difficult to complete. This tolerability difference compared to vidarabine is a key consideration in drug selection, as an effective medication that the patient cannot tolerate is of limited practical value.

Cidofovir is a topical antiviral option that requires only twice daily application due to the long tissue half-lives of its metabolites, contrasting with the five to six times daily dosing required for vidarabine and other topical antivirals. This more practical dosing schedule can significantly improve compliance in many households. However, cidofovir is not commercially available as an ophthalmic preparation and must be compounded, and some concerns about potential nasolacrimal complications with long-term use have been raised.

Famciclovir represents a systemic rather than topical approach to treating FHV-1 infections. This oral medication is converted to its active form penciclovir and has demonstrated both efficacy against FHV-1 and a favorable safety profile in cats. Famciclovir may be used alone for cats that cannot tolerate or cooperate with topical therapy, or in combination with topical antivirals like vidarabine for severe infections requiring comprehensive antiviral coverage.

Cat owners should never substitute medications without veterinary guidance. Some human antivirals, particularly valacyclovir, are severely toxic to cats and must never be administered. The safe use of antiviral medications in cats requires veterinary oversight to select appropriate agents, doses, and monitoring for each individual patient.